Drugs / Trifluridine/Tipiracil Hydrochloride
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06872606 | Apr 2025 → Apr 2026 overdue | rectum adenocarcinoma | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil Hydrochloride | “Drug: Trifluridine/Tipiracil Hydrochloride” NCT06872606 ↗ |
| Route | Oral | “TAS-102 (25 mg/m² orally, days 1-5 and 8-12).” NCT06872606 ↗ |